Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study

BACKGROUND: Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-β ligand (RANKL). Previous reports have shown that denosumab treatment of osteoporotic patients decreases bone resorption and fracture risk, but there have been no clinical studies on...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Yukio, Kamimura, Mikio, Ikegami, Shota, Mukaiyama, Keijiro, Uchiyama, Shigeharu, Taguchi, Akira, Kato, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678608/
https://www.ncbi.nlm.nih.gov/pubmed/26666998
http://dx.doi.org/10.1186/s12902-015-0077-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678608/
https://www.ncbi.nlm.nih.gov/pubmed/26666998
http://dx.doi.org/10.1186/s12902-015-0077-3

Ejemplares similares